Creating Hope Reauthorization Act of 2024

HR 7384, the Creating Hope Reauthorization Act of 2024, extends the deadline for issuing priority review vouchers to pharmaceutical companies developing treatments for rare pediatric diseases. The bill amends the Federal Food, Drug, and Cosmetic Act to push the program’s expiration from 2024 to 2028 and adjusts another related deadline to 2030. This directly affects drug manufacturers seeking faster FDA review for new treatments targeting rare childhood illnesses. The extension ensures continued incentives for developing these critical therapies without altering the core voucher mechanism.